Peselow E D, Goldring N, Stanley M, Barouche F, Fieve R R
Int Clin Psychopharmacol. 1986 Jan;1(1):17-23. doi: 10.1097/00004850-198601000-00003.
The predictive value of the dexamethasone suppression test (DST) was evaluated in two consecutive clinical trials involving 99 individuals treated with amitriptyline or desipramine. Following one week observation, and following one week on low-dose desipramine or amitriptyline (50 mg), all patients who remained depressed (Hamilton score 16 or greater) were given a full clinical trial of either desipramine or amitriptyline (150-300 mg/day) over a minimum 3-5 week period. In all, 68 patients required this trial, 31 receiving amitriptyline and 37 receiving desipramine. For these patients there was no relationship between DST suppression/non-suppression vs clinical response to either desipramine or amitriptyline. There was a non-significant trend for suppressors (negative DST) to respond either spontaneously or to low-dose desipramine or amitriptyline as opposed to non-suppressors (positive DST).
在两项连续的临床试验中，对99名接受阿米替林或地昔帕明治疗的个体评估了地塞米松抑制试验（DST）的预测价值。经过一周的观察，以及在低剂量地昔帕明或阿米替林（50毫克）治疗一周后，所有仍处于抑郁状态（汉密尔顿评分16分或更高）的患者在至少3至5周的时间内接受了地昔帕明或阿米替林（150 - 300毫克/天）的全面临床试验。总共有68名患者需要进行该试验，其中31名接受阿米替林治疗，37名接受地昔帕明治疗。对于这些患者，DST抑制/未抑制与对地昔帕明或阿米替林的临床反应之间没有关联。与未抑制者（DST阳性）相比，抑制者（DST阴性）有自发反应或对低剂量地昔帕明或阿米替林有反应的趋势，但差异无统计学意义。
